[HT-03-1] Overview of clinical aspects of tauopathies including PSP and CBD

Zbgniew Wszolek (Mayo Clinic Florida, USA)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-2] Early pathological changes of CBD

Helen Ling (Queen Square Brain Bank, Institute of Neurology, University College London, UK)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-3] Identification of a gene associated with PSP

Ichiro Yabe (Department of Neurology Faculty of Medicine and Graduate School of Medicine Hokkaido University, Japan)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-4] JALPAC: Longitudinal cohort study for PSP and CBD in Japan

Takeshi Ikeuchi¹, JALPAC Consortium² (1.Brain Research Institute, Niigata University, Japan, 2.JALPAC Consortium)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

[HT-03-5] Molecular imaging for PSP and CBD

Kazunari Ishii (Kindai University Faculty of Medicine, Department of Radiology, Japan)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

Session information